Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of TL-001 in Healthy Adults
NCT06867796Phase 1Active, not recruiting
- Sponsor
- TrueLab Biopharmaceutical
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TL-001 (6 cohorts), sponsored by TrueLab Biopharmaceutical. Primary endpoint: Incidence and severity of Treatment Emergent Adverse Events up to 337 Days. Started Apr 2025; status: active, not recruiting.
02
Drugs
TL-001
Beyond the preview
Go deeper on NCT06867796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06867796.